Learning How to Fight Cancer Ep. 2: Dr. Dan Rubin on The Naturopathic Immune Response
In the second episode of Learning How to Fight Cancer, Immunocine Founder and CEO Dr. Matt Halpert speaks with Dr. Dan Rubin — a board-certified naturopathic oncologist with over 30 years of experience treating complex cancer cases.
This wide-ranging conversation covers both the science and soul of personalized cancer care. Dr. Rubin reflects on how his early work with dendritic cell therapy in the 1990s laid the groundwork for what Immunocine is doing today — and why he’s now fully aligned with the company’s next-generation immunotherapy.
Together, Matt and Dr. Rubin explore:
- Why working with a patient’s own tumor and immune cells is a true expression of naturopathic medicine.
- How Immunocine’s double-loading breakthrough resolves key failures from past dendritic cell therapies.
- Why biological diversity makes one-size-fits-all cancer care ineffective — and what real personalization looks like.
- What patients and caregivers should consider when evaluating integrative or overseas treatment options.
Dr. Rubin also speaks candidly about the importance of vitality, mindset, and trust between patient and doctor:
“You want to live. That’s where it starts. Then you need a plan. A real one. Not a grocery bag of supplements.”
He goes on to affirm his support of Immunocine — not just for its scientific rigor, but for its compassion and transparency:
“The care, the science, the team — it’s all there. And it’s why I refer patients.”
Learn more about Dr. Dan Rubin’s work
- ListenAndCare.com – Naturopathic Specialists
- Rubin On Point – Podcast available on all platforms
READ THIS NEXT
Learning How to Fight Cancer Ep. 6: Optimizing Metabolism to Lower Inflammation with Dr. Janet Maendel
In this episode of Learning How to Fight Cancer, Dr. Matt Halpert sits down with Dr. Janet Maendel, founder of Nurture & Restore Wellne
Read More
Three Years After Treatment Kevin Cox Remains Cancer-Free
Three years ago, Kevin was navigating one of the most uncertain times of his life. After a Stage 2C melanoma diagnosis and a recurrence that
Read More
Defying a 1% Prognosis: Pete’s Fight Against a Rare Brain Cancer
When Pete was diagnosed with a Grade 4 diffuse astrocytoma, doctors told him he had a 1% chance of being alive in eight months. Th
Read More
